Recalcitrant dermatoses: Patients who frequently relapse Rebound of pre-existing dermatoses can occur with abrupt discontinuation of clobetasol. Therapy with clobetasol should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy. The maximum weekly dose should not exceed 50gms/week. If continuous treatment is necessary, a less potent preparation should be used. Treatment should not be continued for more than 4 weeks. If the condition worsens or does not improve within 2-4 weeks, treatment and diagnosis should be re-evaluated. Thereafter improvement can usually be maintained by application without occlusion. Overnight occlusion only is usually adequate to bring about a satisfactory response. In more resistant lesions, especially where there is hyperkeratosis, the effect of ClobaDerm can be enhanced, if necessary, by occluding the treatment area with polythene film. Repeated short courses of ClobaDerm may be used to control exacerbations. Allow adequate time for absorption after each application before applying an emollient. Repeated but short courses of clobetasol propionate may be used to control exacerbations (see details below).Īpply thinly and gently rub in using only enough to cover the entire affected area once or twice a day until improvement occurs (in the more responsive conditions this may be within a few days), then reduce the frequency of application or change the treatment to a less potent preparation. If treatment with a local corticosteroid is clinically justified beyond 4 weeks, a less potent corticosteroid preparation should be considered. Date of first authorisation/renewal of the authorisationĬlobetasol propionate belongs to the most potent class of topical corticosteroids (Group IV) and prolonged use may result in serious undesirable effects (see section 4.4). 6.6 Special precautions for disposal and other handling.4.7 Effects on ability to drive and use machines.4.5 Interaction with other medicinal products and other forms of interaction.4.4 Special warnings and precautions for use.4.2 Posology and method of administration.Show table of contents Hide table of contents
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |